Cerus Corporation (CERS)
$2.26+0.00%Close
SELLCRISIS · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $453M
- Beta
- 1.83
- P/E (TTM)
- -62.43
- Short % float
- 9.28%
- Days to cover
- 8.0
- SI change
- -2.3%
- 1W
- -3.42%
- 1M
- -11.37%
- vs SPY 1W
- -3.28%
- vs SPY 1M
- -13.88%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 9
- GROWTH
- 41
- GARP
- 3
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC-6.2%
REV YoY-
ROE-10.3%
EPS YoY-
ROA-3.3%
GROSS52
OP-1
NET-3
[VALUATION]
P/E TTM-62.43
P/E FWD-
SECTOR PE20.34
INDUSTRY PE22.66
P/B6.47
P/FCF-
EV/EBITDA176.85
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E109.68
ALTMAN Z-
CURR RATIO1.83
ND/EBITDA-
BETA1.83
Company news
FAQ
- What is LOPJLB’s current signal on CERS?
- LOPJLB’s latest quantitative signal on Cerus Corporation (CERS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CERS in?
- Cerus Corporation (CERS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cerus Corporation (CERS) do?
- Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathog…